International experience of laboratory methods in the cervical cancer screening
- Authors: Enaeva M.V.1, Noskova K.K.1
-
Affiliations:
- The Loginov Moscow Clinical Scientific Center
- Issue: Vol 26, No 5 (2021)
- Pages: 177-187
- Section: Reviews
- URL: https://journals.rcsi.science/1028-9984/article/view/111127
- DOI: https://doi.org/10.17816/onco111127
- ID: 111127
Cite item
Abstract
Cervical cancer (CC) is a serious health problem all over the world. CC is a fully preventable disease; however, it remains one of the leading causes of death among women with carcinomas. The screening helps to reduce morbidity and mortality. Two tests are used as screening tests in the world: сervical cytology and detection of human papillomavirus (HPV). Cervical cytology (Pap test) is a traditional test of CC screening. Two types of Pap test are used in modern laboratory practice: liquid and traditional methods. HPV testing is now used as the primary screening tool for СС in some countries. However, a key factor in effective screening is the coverage of the population and the organization of the screening. Immunocytochemical examination is an additional method used to improve the accuracy of diagnosis, p16/Ki-67 dual staining. This review focuses on the laboratory methods used in the world practice of screening. The literature search for this review was conducted using PubMed, MedLine and Embase.
Full Text
##article.viewOnOriginalSite##About the authors
Marina V. Enaeva
The Loginov Moscow Clinical Scientific Center
Author for correspondence.
Email: m.enaeva@mknc.ru
ORCID iD: 0000-0003-2537-2284
SPIN-code: 9817-5470
Russian Federation, Moscow
Karina K. Noskova
The Loginov Moscow Clinical Scientific Center
Email: k.noskova@mknc.ru
ORCID iD: 0000-0001-5734-0995
SPIN-code: 1241-0195
MD, Cand. Sci. (Med.)
Russian Federation, MoscowReferences
- Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2020. CA Cancer J Clin. 2020;70(1):7–30. doi: 10.3322/caac.21590
- Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers iN 185 countries. CA Cancer J Clin. 2021;71(3): 209–49. doi: 10.3322/caac.21660
- Kaprin AD, Starinskij VV, Petrova GV. Malignant neoplasms in Russia in 2018 (Morbidity and mortality). FGBU «MNIOI im. P.A. Gercena» Minzdrava Rossii. 2019. (In Russ).
- Aksel EM, Vinogradova NN. Statistics of malignant neoplasms of female reproductive organs. Gynecologic Oncology. 2018;(3):64–78. (In Russ.).
- Cochrane AL, Holland WW. Validation of screening procedures. Br Med Bull. 1971;27(1): 3–8. doi: 10.1093/oxfordjournals.bmb.a070810
- Chrysostomou AC, Stylianou DC, Constantinidou A, Kostrikis LG. Cervical Cancer Screening Programs in Europe: the transition towards HPV vaccination and population-based HPV testing. Viruses. 2018;10(12):729. doi: 10.3390/v10120729
- Toropovskiy AN, Pavlova ON, Viktorov DA, et al. Cervical cancer epidemiology and significance of its diagnosis and screening (literature review). Gynecologic Oncology. 2019;(4):45–53. (In Russ).
- Papanicolaou GN, Traut HF. The diagnostic value of vaginal smears in carcinoma of the uterus. Am J Obstet Gynecol. 1941;42(2):193. doi: 10.1016/S0002-9378(16)40621-6
- Cervical cancer screening programs: summary of the 1982. Canadian Task Force report. Can Med Assoc J. 1982;127(7):581–9.
- Ng E, Wilkins R, Fung MF, Berthelot JM. Cervical cancer mortality by neighbourhood income in urban Canada from 1971 to 1996. Can Med Assoc J. 2004;170(10):1545–9. doi: 10.1503/cmaj.1031528
- Maxwell CJ, Bancej CM, Snider J, Vik SA. Factors important in promoting cervical cancer screening among Canadian women: Findings from the 1996–97 national population health survey (NPHS). Can J Public Health. 2001;92(2):127–33. doi: 10.1007/BF03404946
- Bray F, Loos A, McCarron P, et al. Trends in cervical squamous cell carcinoma incidence in 13 European countries: Changing risk and the effects of screening. Cancer Epidemiol Biomarkers Prev. 2005;14(3):677–86. doi: 10.1158/1055-9965.EPI-04-0569
- ACOG. Practice Bulletin No. 168: cervical cancer screening and prevention. Obstet Gynecol. 2016; 128(4): e111–30. doi: 10.1097/AOG.0000000000001708
- Toropovskiy AN, Pavlova, Viktorov DA, Nikitin AG. New screening and diagnostic methods for cervical cancer. Bulletin of the Medical Institute «REAVIZ» (REHABILITATION, DOCTOR AND HEALTH). 2019;4 :51–64. (In Russ).
- Novik VI. Discussion questions of cytological screening of cervical cancer (literature review). Tumors of Female Reproductive System. 2020;16(2):63–71. (In Russ). doi: 10.17650/1994-4098-2020-16-2-63-71
- Minkina GN. Cytological screening of the cervical cancer: from the traditional Pap test to computer technologies. Obstetrics, Gynecology and Reproduction. 2017;11(1):56–63. (In Russ). doi: 10.17749/2313-7347.2017.11.1.056-063
- Nanda K, McCrory DC, Myers ER, et al. Accuracy of the Papanicolaou test in screening for and follow-up of cervical cytologic abnormalities: a systematic review. Ann Intern Med. 2000;132(10):810–9. doi: 10.7326/0003-4819-132-10-200005160-00009
- Srisomboon S, Tantipalakorn C, Charoenkwan K, Srisomboon J. Cervical screening results leading to detection of adenocarcinoma in situ of the uterine cervix. Asian Pac J Cancer Prev. 2019;20(2):377–382. doi: 10.31557/APJCP.2019.20.2.377
- Savostikova MV, Korolenkova LI, Fedoseeva ES, Pimenova VV. The experience of the use of liquid-based technology BD SUREPATH™ for early diagnosis and screening for cervical precancerous lesions and cervical cancer in Rostov region. Gynecologic Oncology. 2018;4:50–60. (In Russ).
- Bollman N R. Liquid-based cytology for risk-adapted cervical screening. Reproductive Endocrinology. 2015;(21):95–101. doi: 10.18370/2309-4117.2015.21.95-101
- Rozemeijer K, Naber SK, Penning C, Overbeek LI, et al. Cervical cancer incidence after normal cytological sample in routine screening using SurePath, ThinPrep, and conventional cytology: population based study. BMJ. 2017;356:j504. doi: 10.1136/bmj.j504
- Rozemeijer K, Penning C, Siebers AG, et al. Comparing SurePath, ThinPrep, and conventional cytology as primary test method: SurePath is associated with increased CIN II+ detection rates. Cancer Causes Control. 2016;27(1):15–25. doi: 10.1007/s10552-015-0678-1
- Phaliwong P, Pariyawateekul P, Khuakoonratt N, Sirichai W, et al. Cervical Cancer detection between conventional and liquid based cervical cytology: a 6-year experience in Northern Bangkok Thailand. Asian Pac J Cancer Prev. 2018;19(5):1331–36. doi: 10.22034/APJCP.2018.19.5.1331
- Ito K, Kimura R, Konishi H, et al. A comparison of liquid-based and conventional cytology using data for cervical cancer screening from the Japan Cancer Society. Jpn J Clin Oncol. 2020;50(2):138–144. doi: 10.1093/jjco/hyz161
- Hosono S, Terasawa T, Katayama T, Sasaki S, et al. Hosono S, Terasawa T, Katayama T, Sasaki S, et al. Frequency of unsatisfactory cervical cytology smears in cancer screening of Japanese women: a systematic review and meta-analysis. Cancer Sci. 2018;109(4):934–43. doi: 10.1111/cas.13549
- Boshart M, GissmanN L, Ikenberg H, et al. A new type of papillomavirus DNA, its presence in genital cancer biopsies and in cell lines derived from cervical cancer. EMBO J. 1984;3(5):1151–7. doi: 10.1002/j.1460-2075.1984.tb01944.x
- Schwarz E, Freese UK, Gissmann L, et al. Structure and transcription of human papillomavirus sequences in cervical carcinoma cells. Nature. 1985;314(6006):111–4. doi: 10.1038/314111a0
- de Villiers EM, Wagner D, Schneider A, et al. Human papillomavirus infections in women with and without abnormal cervical cytology. Lancet. 1987;2(8561):703–6. doi: 10.1016/s0140-6736(87)91072-5
- Okunade KS. Human papillomavirus and cervical cancer. J Obstet Gynaecol. 2020;40(5):602–8. doi: 10.1080/01443615.2019.1634030
- Salazar KL, Duhon DJ, Olsen R, Thrall M. A review of the FDA-approved molecular testing platforms for human papillomavirus. J Am Soc Cytopathol. 2019;8(5):284–92. doi: 10.1016/j.jasc.2019.06.001
- Sitarz K, Szostek S. Food and drug administration – approved molecular methods for detecting human papillomavirus infection. Ginekol Pol. 2019;90(2):104–8. doi: 10.5603/GP.2019.0018
- PAHO. Integrating HPV testing in cervical cancer screening program: a manual for program managers. Washington, D.C. : PAHO, 2016 [cited 2020 Jul 9]. Available from: https://www.paho.org/hq/dmdocuments/2016/manual-VPH-English-FINAL-version.pdf.
- Meijer CJ, Berkhof J, Castle PE, et al. Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older. Int J Cancer. 2009;124(3):516–20. doi: 10.1002/ijc.24010
- Alameda F, Garrote L, Mojal S, Sousa C, et al. Cervista HPV HR test for cervical cancer screening: a comparative study in the Catalonian population. Arch Pathol Lab Med. 2015;139:241–4. doi: 10.5858/arpa.2014-0012-OA
- Ejegod DM, Hansen M, Christiansen IK, et al. Clinical validation of the Cobas 4800 HPV assay using cervical samples in SurePath medium under the VALGENT4 framework. J Clin Virol. 2020;128:104336. doi: 10.1016/j.jcv.2020.104336
- Iftner T, Neis KJ, Castanon A, Landy R, et al. Longitudinal clinical performance of the RNA-based Aptima Human Papillomavirus (AHPV) Assay in comparison to the DNA-based Hybrid Capture 2 HPV test in two consecutive screening rounds with a 6-year interval in Germany. J Clin Microbiol. 2019;57(1):e01177–18. doi: 10.1128/JCM.01177-18
- Bonde JH, Pedersen H, Quint W, et al. Clinical and analytical performance of the BD Onclarity HPV assay with SurePath screening samples from the Danish Cervical Screening Program using the VALGENT framework. J Clin Microbiol. 2020;58(2):e01518–19. doi: 10.1128/JCM.01518-19
- Iftner T, Wang L, Iftner A, Holz B, et al. Study-based evaluation of the Abbott RealTime High Risk HPV test in comparison to the HC2 HR HPV test in women aged ≥30 years using residual LBC ThinPrep specimens. BMC Infect Dis. 2016;16(1):672. doi: 10.1186/s12879-016-1994-0
- IARC. Cervix Cancer Screening: IARC Handbooks of Cancer Prevention. Vol. 10. Lyon : IARC Press, 2005. 302 p.
- Tewari P, White C, Kelly L, Pilkington L, et al. Clinical performance of the Cobas 4800 HPV test and the Aptima HPV assay in the management of women referred to colposcopy with minor cytological abnormalities. Diagn Cytopathol. 2018;46(12):987–92. doi: 10.1002/dc.24066
- Bottari F, Boveri S, Iacobone AD, Gulmini C, et al. Transition from Hybrid Capture 2 to Cobas 4800 in HPV detection: sensitivity and specificity for Cin2+ in two time periods. Infect Dis (Lond). 2018;50(7):554–9. doi: 10.1080/23744235.2018.1441538
- Curry SJ, Krist AH, Owens DK; US Preventive Services Task Force, et al. Screening for cervical cancer: US Preventive Services Task Force Recommendation Statement. JAMA. 2018;320(7):674–86. doi: 10.1001/jama.2018.10897
- Tjalma WAA. Diagnostic performance of dual-staining cytology for cervical cancer screening: A systematic literature review. Eur J Obstet Gynecol Reprod Biol. 2017;210:275–80. doi: 10.1016/j.ejogrb.2017.01.009
- Zhang R, Ge X, You K, et al. p16/Ki67 dual staining improves the detection specificity of high-grade cervical lesions. J Obstet Gynaecol Res. 2018;44(11):2077–84. doi: 10.1111/jog.13760
- Kyrgiou M, ArbyN M, BergeroN C, Bosch FX, et al. Cervical screening: ESGO-EFC position paper of the European Society of Gynaecologic Oncology (ESGO) and the European Federation of Colposcopy (EFC). Br J Cancer. 2020;123(4):510–7. doi: 10.1038/s41416-020-0920-9
- Allia E, Ronco G, Coccia A, et al. Interpretation of p16(INK4a) /Ki-67 dual immunostaining for the triage of human papillomavirus-positive women by experts and nonexperts in cervical cytology. Cancer Cytopathol. 2015;123(4):212–8. doi: 10.1002/cncy.21511
- Bergeron C, von Knebel Doeberitz M. The Role of cytology in the 21st century: the integration of cells and molecules. Acta Cytol. 2016;60(6):540–2. doi: 10.1159/000449402
- von Knebel Doeberitz M. New molecular tools for efficient screening of cervical cancer. Dis Markers. 2001;17(3):123–8. doi: 10.1155/2001/249506
- Shiraz A, Crawford R, Egawa N, et al. The early detection of cervical cancer. The current and changing landscape of cervical disease detection. Cytopathology. 2020;31(4):258–70. doi: 10.1111/cyt.12835
- Magkana M, Mentzelopoulou P, Magkana E, et al. The p16/Ki-67 assay is a safe, effective and rapid approach to triage womeN with mild cervical lesions. PLoS One. 2021 Jun [cited 2021 Dec 12];16(6):e0253045 [18 p.]. doi: 10.1371/journal.pone.0253045
- Ebisch RM, van der Horst J, Hermsen M, et al. EvaluatioN of p16/Ki-67 dual-stained cytology as triage test for high-risk human papillomavirus-positive women. Mod Pathol. 2017;30(7):1021–31. doi: 10.1038/modpathol.2017.16
- Li YC, Zhao YQ, Li TY, et al. The performance of immunocytochemistry staining as triaging tests for high-risk HPV-positive women: a 24-month prospective study. J Oncol. 2020 May [cited 2021 Dec 12]; 2020:6878761 [8 p.]. Available from: https://downloads.hindawi.com/journals/jo/2020/6878761.pdf. doi: 10.1155/2020/6878761
- Uijterwaal MH, PolmaN NJ, Witte BI, et al. Triaging HPV-positive women with normal cytology by p16/Ki-67 dual-stained cytology testing: baseline and longitudinal data. Int J Cancer. 2015;136(10):2361–8. doi: 10.1002/ijc.29290
- Abreu AL, Silva RA, Fernandes S. Validation of CINtec® PLUS cytology kit in the diagnosis of persistent HPV infections – cohort study in the Portuguese population. J Cytol. 2021;38(2):94–100. doi: 10.4103/JOC.JOC_173_20
- Bergeron C, Ikenberg H, Sideri M, Denton K; PALMS Study Group, et al. Prospective evaluation of p16/Ki-67 dual-stained cytology for managing women with abnormal Papanicolaou cytology: PALMS study results. Cancer Cytopathol. 2015;123(6):373–81. doi: 10.1002/cncy.21542
- Wright TC Jr, Behrens CM, Ranger-Moore J, et al. Triaging HPV-positive women with p16/Ki-67 dual-stained cytology: Results from a sub-study nested into the ATHENA trial. Gynecol Oncol. 2017;144(1):51–6. doi: 10.1016/j.ygyno.2016.10.031
- Benevolo M, Allia E, Gustinucci D; New Technologies for Cervical Cancer Screening 2 (NTCC2) Working Group, et al. Interobserver reproducibility of cytologic p16INK4a/Ki-67 dual immunostaining in human papillomavirus-positive women. Cancer Cytopathol. 2017;125(3):212–20. doi: 10.1002/cncy.21800